

Review Article

Systematic Review and Meta-Analysis on Randomized Controlled Trials on Efficacy and Safety of Panax Notoginseng Saponins in Treatment of Acute Ischemic Stroke

Liu-ding Wang ,^{1,2} Zhen-min Xu ,³ Xiao Liang ,¹ Wen-ran Qiu ,¹ Shao-jiao Liu ,³ Ling-ling Dai ,³ Ye-fei Wang ,³ Chun-yan Guo ,³ Xiang-hua Qi ,⁴ Jian Wang ,⁵ Yan-bing Ding ,⁶ Yun-ling Zhang ,¹ and Xing Liao ,²

¹Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

²Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine,

China Academy of Chinese Medical Sciences, Beijing 100700, China

³Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China

⁴The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China

⁵The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun 130021, China

⁶Chinese Medicine Hospital of Hubei Province, Wuhan 430074, Hubei, China

Correspondence should be addressed to Yun-ling Zhang; yunlingzhang2004@163.com and Xing Liao; okfrom2008@hotmail.com

Received 21 April 2021; Revised 10 June 2021; Accepted 28 June 2021; Published 12 July 2021

Academic Editor: Amin Tamadon

Copyright © 2021 Liu-ding Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Importance. Panax Notoginseng Saponins (PNS) are proven to have antiplatelet effects in patients with acute ischemic stroke (AIS). Objective. To assess the efficacy and safety of PNS on antiplatelet therapy in the treatment of AIS. Methods. We searched 7 literature databases and 2 clinical studies databases for randomized controlled studies (RCTs) evaluating PNS as an adjuvant therapy for AIS. Relevant studies were retrieved and screened, and data were extracted independently by two reviewers. The quality of the included studies was assessed using the Cochrane Risk Assessment Tool. Meta-analysis was carried out with the Rev Man 5.4 software. Results. Of 8267 records identified, 43 RCTs met our inclusion criteria (n = 4170 patients). Patients assigned to PNS with conventional treatments (CTs) had improved functional independence at 90 days compared with those assigned to CTs alone (RR = 1.87, 95% CI = 1.37, to 2.55, P < 0.0001). Patients who received PNS combined with CTs showed significantly high improvements in neurological function among individuals with AIS on the neurologic deficit score (NDS) ($MD_{CSS} = -5.71, 95\%$ CI = -9.55 to -1.87, P = 0.004; $MD_{NIHSS} = -3.94$, 95% CI = -5.65 to -2.23, P < 0.00001). The results also showed PNS contributed to a betterment in activities of daily living (ADL) on the Barthel index ($MD_{day \ 10 \ BI}$ = 4.86, 95% CI = 2.18, to 7.54, P < 0.00001; $MD_{day \ 14 \ BI} = 13.92, 95\% \ CI = 11.46$ to 16.38, $P < 0.00001; \ MD_{day \ 28 \ BI} = 7.16, 95\% \ CI = 0.60$, to 13.72, P < 0.00001). In addition, PNS, compared with CTs alone, could significantly improve overall response rate (ORR) (RR_{NIHSS} = 1.20, 95% CI = 1.16, to 1.24, P < 0.00001; $RR_{CSS} = 1.15$, 95% CI = 1.08, to 1.24, P < 0.0001), hemorheological parameters, maximum platelet aggregation rate (MPAR) (MD = -6.82, 95% CI = -9.62 to -4.02, P < 0.00001), platelet parameters $(MD_{PLT} = 4.85, 95\% CI = 1.82 \text{ to } 7.84, P = 0.002;$ $MD_{MPV} = -0.79, 95\%$ CI = -1.09 to -0.48, P < 0.00001), and serum CD62P (MD = -0.21, 95% CI = -0.29 to -0.13, P < 0.00001). The incidence of adverse reactions in PNS was lower than that in the control group (RR = 0.62, 95% CI = 0.39 to 0.97, P = 0.04). Adverse reactions in the PNS were mild adverse reactions. Conclusion. PNS may be effective and safe in treating AIS on ameliorating neurological deficit, improving activities of daily living function, and enhancing antiplatelet effects. However, more high-quality evidence is needed before it can be recommended for routine antiplatelet therapy in patients with AIS.

1. Introduction

Acute ischemic stroke (AIS), also known as acute cerebral infarction (ICD10 Code: i63.902), is a life-threatening medical condition with a high incidence that carries a grave prognosis if not addressed promptly. It is characterized by acute onset. According to epidemiological studies, there are about 17 million patients with AIS in the world every year [1], and 6.2 million people die from AIS [2]. The mortality and disability rate of patients with AIS in China is 34.5%-37.1% within 3 months after the onset of disease [3, 4]. Its pathogenesis is sudden occlusion of the cerebral artery, resulting in cerebrovascular circulation dysfunction and irreversible neuronal necrosis [5]. At present, conventional treatments recommended by clinical practice guidelines include thrombolytic drugs, antiplatelet drugs, anticoagulants, and neurotrophic drugs. However, there are side effects and drug resistance, such as intracerebral bleeding after thrombolysis [6] and clopidogrel resistance [7]. Naturally, reducing the rate of intracranial hemorrhage after reperfusion and overcoming clopidogrel resistance are the requirements of new antiplatelet drugs in the future.

Panax Notoginseng Saponins (PNS), an active ingredient extracted from Chinese herbal medicine Panax notoginseng, has been widely used in the treatment of AIS in China. Panax notoginseng is traditionally applied as an activating blood drug, also known as Sanqi or Tianqi. Sanqi was first recorded in the "Compendium of Materia Medica" (Bencao Gangmu) in 1758, in which it was called "more precious than gold" (jinbuhuan). Its preparations include Xuesaitong injection, Xueshuantong injection, Lulutong injection, Xuesaitong capsules, Xueshuantong capsules, Sanqi Tongshu capsules, and Xuesaitong dropping pills. In recent five years, systematic reviews to evaluate the efficacy of PNS have been published [8-11]. Pharmacological experiments to study the mechanism of PNS showed the effects on anti-ischemia-reperfusion injury [12]. The synergistic mechanism of Chinese herbal medicine and antiplatelet drugs of western medicine has caught worldwide attention. It was found that PNS could enhance the antiplatelet effect by regulating the arachidonic acid (AA) metabolic pathway [13], inhibiting thromboxane A2 (TXA2) [14] or aspirin hydrolase [15], and increasing the $AUC_{0-\infty}$ or Cmax of the clopidogrel active metabolite [16].

However, most of the existing systematic reviews observed a certain kind of PNS preparations [8, 11] and paid more attention to the efficacy of PNS combined with a certain western medicine [9, 10], such as Xueshuantong combined with edaravone or butylphthalide, but was lacking in the latest clinical research results to evaluate the therapeutic effect of PNS as the only variable in the intervention and control group. In this study, RCTs of PNS in the treatment of AIS were selected for systematic review and meta-analysis, in order to provide up-to-date evidence for clinical application of PNS.

2. Information and Methods

2.1. Research Registrations. This systematic review protocol was registered with PROSPERO (PROSPERO Registration:

CRD42021229265). The protocol is shown in Supplementary files.7.

2.2. Data Sources and Search Strategy. The current systematic review was part of the project "Identification of Priorities for Improvement of Implementation on Evidence-Based Traditional Chinese Medicine" (zz13-024-3). Based on this project, databases such as CNKI, Wanfang, VIP, CBM, EMBASE, PubMed, Cochrane Library, ClinicalTrials.gov, and ChiCTR were searched by the research team. A separate database of AIS treated with traditional Chinese medicine was established. The retrieval time is from the establishment of the database to December 2020. The database classified the literature systematically according to the types of research and intervention measures. Considering that the above search did not explicitly mention PNS, we conducted an additional search by using keywords including PNS, Xuesaitong, Xueshuantong, Sanqi Tongshu capsule, and Lulutong and supplemented the database of PNS in the treatment of AIS. Taking PubMed as an example, the specific supplementary retrieval strategies are presented in Supplementary File 1. On 4 April 2021, we updated the database search of PubMed and CNKI. We used the same search method, except that we narrowed the searches to 2020 onwards.

2.3. Inclusion Criteria

2.3.1. Types of Studies. Randomized controlled trials (RCTs) were included.

2.3.2. Types of Participants. Patients diagnosed with AIS were included.

2.3.3. *Types of Interventions*. The experimental group treated with PNS combined with conventional treatments (CTs) and the control group treated with the same CTs were included. CTs are considered to include thrombolytic drugs, antiplatelets, anticoagulants, statins, neuroprotective agents, and antihypertensive and collateral circulation drugs.

2.3.4. Types of Outcomes. Efficacy outcomes: the primary outcome was a 3-month functional independence rate (mRS scores 0–2), and the secondary outcomes were neurologic deficit score (NDS), ADL-Barthel score, overall response rate (ORR), hemorheological parameters, maximum platelet aggregation rate (MPAR), platelet parameters, CD62P, and coagulation function.

Safety outcomes: incidence of adverse reactions and adverse reactions.

2.4. Exclusion Criteria. We excluded trials as follows: (1) other TCM treatments were applied in either treatment or control group; (2) full texts were not available; (3) data is not complete; (4) language is not Chinese or English.

2.5. Study Selection. Two reviewers (LDW and ZMX) independently performed literature selection according to the predefined eligibility criteria. The records retrieved in all databases were imported into NoteExpress3.2, and the duplicated records were deleted. Records were first screened based on the title and abstract, and in cases of uncertainty, the full texts were obtained. Any disagreement between the paired reviewers was resolved through discussing with a third reviewer (XL).

2.6. Data Extraction. Data extraction was conducted by two reviewers (LDW and WRQ) using a standardized, predetermined data extraction form. Two reviewers independently extracted data from each trial and then cross-checked the data. Discrepancies were solved by discussion between the two reviewers or arbitrated by the senior researcher (XL) if necessary. We extracted the following data: (1) study characteristics, (2) participant's baseline characteristics and inclusion/exclusion criteria, (3) details of intervention and control groups, and (4) outcomes (dichotomous data were the number of events and total participants per group; continuous data were presented as mean, standard deviation, and total participants per group).

2.7. Methodological Quality Assessment. Two reviewers (LDW and SJL) independently assessed the risk of bias of the included trials. According to the Cochrane Risk of Bias tool [17], seven fields of risk of bias were evaluated as follows: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The other bias includes the following aspects, comparable baseline, sample size calculation, participation of pharmaceutical enterprises, and deception. The evaluation results were ranked as "low risk," "unclear risk," or "high risk." If disagreements on the assessment were identified, the researcher (XL) was consulted.

2.8. Data Analysis. Review Manager software (RevMan, version 5.4) was utilized to conduct the data analysis of dichotomous and continuous outcomes, which were extracted from the primary studies. Risk ratio (RR) was used for dichotomous data while weighted mean difference (WMD) or standardized mean difference (SMD) were adopted for continuous variables as effect size, both of which were demonstrated with effect size and 95% confidence intervals (CI). When no statistical heterogeneity was identified (heterogeneity test, $P \ge 0.10$, or $I^2 \le 50\%$), a fixed-effects model was selected; otherwise, a random-effects model was applied. We would perform subgroup analyses and sensitivity analyses based on the course of treatment or dose or follow-up time. Sources of heterogeneity will be fully explored if enough data are available. A funnel plot was used to detect the publication bias if the number of included trials was larger than ten for an outcome. Statistical significance was set at P < 0.05.

2.9. Reporting Bias Assessment. To assess small-study effects, we planned to generate funnel plots for meta-analyses including at least 10 trials of varying size to detect the publication bias. To assess outcome reporting bias, we compared the outcomes specified in trial protocols with the outcomes reported in the corresponding trial publications; if trial protocols were unavailable, we compared the outcomes reported in the methods and results sections of the trial publications.

2.10. Certainty Assessment. Two reviewers (LDW and CYG) independently assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach [18] and assessed the certainty of the evidence as "high," "moderate," "low," or "very low." The certainty can be downgraded for five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) and upgraded for three reasons (large magnitude of an effect, dose-response gradient, and effect of plausible residual confounding).

3. Results

3.1. Study Selection. The search yielded 8267 records. There were 5015 duplicates, leaving 3252 to be screened by title and abstract from which 53 eligible records were retained for full-text evaluation. After careful evaluation and no disagreements between the two reviewers, 10 reports were excluded. Ultimately, 43 reports involving 4170 participants met our inclusion criteria [19–61]. See Figure 1 for details of the flow diagram with the search results and selection of studies. A list of 9 studies that might appear to meet the inclusion criteria but which were excluded, with citation and the reason for exclusion, is reported in Supplementary File 2.

3.2. Study Characteristics. All 43 included RCTs were performed in China. All interventions were PNS in combination with CTs. Among them, 17 studies [19, 23, 24, 28-31, 35, 36, 38-40, 44, 45, 49, 51, 61] were Xueshuantong injection, 18 [20-22, 25-27, 31, 32, 34, 37, 41-43, 46-48, 50, 52] were Xuesaitong injection, 5 [53-57] were Sanqi Tongshu capsule, 1 [58] was Xuesaitong Soft Capsule, 1 [59] was Xuesaitong dropping pill, and 1 [60] was Xueshuantong capsule. The proportion of functional independence at 3 months was reported by 1 study [36]. The total effective rate was reported by 37 studies [20-24, 26, 28, 29, 31-46, 49-61], of which 32 studies [20-22, 24, 26, 28, 29, 31, 33-46, 49-52, 54-57, 59, 61] adopted the clinical efficacy scoring standard formulated by the fourth national cerebrovascular conference, and 5 studies [23, 32, 53, 58, 60] adopted other efficacy standards. Neurological deficit scores were reported by 26 studies [21-23, 29-35, 38-41, 43, 46, 50-54, 56-58, 60, 61], of which 22 [21-23, 29-34, 38-40, 43, 46, 52-54, 56-58, 60, 61] used NIHSS and 4 [35, 41, 50, 51] used CSS. The other details are shown in Supplementary File 3. The characteristics of different PNS preparations are shown in Supplementary File 4.




FIGURE 1: Flow diagram for identification of studies.


3.3. Methodological Quality Assessment. We have summarized the risks of bias in the included trials in Figure 2. For "random sequence generation," we rated twenty-four trials as having a low risk of selection bias because the authors reported a suitable randomization process, of which twentyone trials [20-26, 28, 29, 32, 34, 35, 37-42, 51, 52, 55] used a random number table, two trials [53, 56] used systematic randomization, and one trial [30] used a lottery. Fourteen trials had an unclear risk of bias for this domain due to the lack of an adequate description of how the random sequence generation was conducted. Three trials had a high risk of bias for the domain due to the random sequence generated by admission date [60] and admission order [27, 46]. For "allocation concealment," we considered the risk of bias to be unclear in forty-three trials, on account of the lack of reporting the allocation concealment methodology. For "blinding," we rated one trial as having a low risk of bias because the authors explicitly reported blinding was implemented. And we judged forty-two trials as an unclear risk due to the absence of information regarding blinding of participants, personnel, and outcome assessment. For


"incomplete outcome data," we rated the risk of attrition bias as unclear in forty-three trials because the authors did not mention the loss of follow-up. For "selective reporting," we considered forty-two trials as having a low risk of bias due to reported the preset outcomes. We judged one trial [41] as having a high risk of reporting bias because the appropriate data about the predesigned outcome was unavailable. It is not clear whether there are other biases.

3.4. Efficacy Outcomes

3.4.1. 3-Month Functional Independence Rate. There is one study [36] that reported the functional independence rate three months after treatment. The result demonstrated that the 3-month functional independence rate for the PNS plus CTs was significantly higher than that of CTs alone (RR = 1.87, 95% CI = 1.37, to 2.55, P < 0.0001; Figure 3).

3.4.2. NDS. Twenty-six studies reported NDS on days 7, 10, 14, 15, 21, 28, 30, 56, and 90, respectively. Due to the








FIGURE 3: 3-month functional independence rate: PNS plus CTs vs. CTs.

substantial clinical heterogeneity and inconsistency of observation time points among studies, descriptive analysis was conducted according to the treatment time. The results are shown in Figure 4. There was no statistically significant difference in the NDS of the two studies [32, 46], while there were statistically significant differences in other studies. PNS plus CTs was related to a substantial reduction in NDS.

The number of studies that observed NDS at 14 days was large; therefore, the quantitative analysis of this outcome was carried out separately. Since the different scoring standards led to significant clinical heterogeneity, which will affect the stability of the results, subgroup analysis was conducted, with the result that PNS plus CTs was associated with an evident decrease in NIHSS and CSS ($MD_{CSS} = -5.71$, 95% CI = -9.55 to -1.87, P = 0.004; $MD_{NIHSS} = -3.94$, 95% CI = -5.65 to -2.23, P < 0.00001; Figure 5). The heterogeneity between studies of two subgroups was large ($I^2 = 97\%$, P < 0.00001); therefore, a random-effects model was used.

Sensitivity analysis was carried out, but the differences in the dose or duration of interventions in different studies that may cause these heterogeneities have not been found. It was suspected that different drugs of CTs resulted in heterogeneity. The results were limited by substantial heterogeneity to a certain extent.

3.4.3. ADL-Barthel Score. A total of seven studies [19, 23, 29, 38, 45, 56, 57] measured the changes in the ADL-Barthel score. Subgroup analysis was carried out according to different observation time points. Among the studies comparing PNS plus CTs vs. CTs alone, there was a consequential difference in the ADL-Barthel score: PNS plus CTs, as compared with CTs independently, was associated with a significant improvement in ADL-Barthel score ($MD_{day \ 10 \ BI}$ = 4.86, 95% CI = 2.18, to 7.54, P < 0.00001; $MD_{day \ 14 \ BI}$ = 13.92, 95% CI = 11.46 to 16.38, P < 0.00001; $MD_{day \ 28 \ BI}$ = 7.16, 95% CI = 0.60, to 13.72, P < 0.00001; Figure 6). Nevertheless, significant heterogeneity was identified among the studies (I^2 = 50%, P = 0.09), so a random-effects model was used.

After sensitivity analysis and careful reading of the original literature, we found that the study sites of two studies [19, 38] were quite different from those of three other studies, which were probably the major source of the heterogeneity. Tongliao and Urumqi were the sites

udy or subgroup		NS + C SD		Mean	CTs SD T	Fotal	Weight (%)	Mean differen IV, random, 95%		Mean difference IV, random, 95% CI	Risk of bias A B C D E F G
1.1. NDS _{7d}											
heng Mingxia 2014 en Shan 2018	9.53 2.58	3.45 0.78	33 40	10.05		30 40	3.0 3.4	-0.52 [-2.31, 1.		-	3● 2228●
ubtotal (95% CI)	2.30	0.78	73	3.6		70	6.4	-1.02 [-1.53, -0 -0.98 [-1.47, -0		•	● ? ? ? ? ●
eterogeneity: tau ² =).00; chi	$^{2} = 0.2$		= 1 (P =					,	· ·	
est for overall effect:	Z = 3.90	(P < 0)	0.000	i)							
1.2. NDS _{10d}	9.74	1.75	40	11.68	2.14	49	3.3	104[27] 1	171		
nang Xin 2020 Ibtotal (95% CI)	9.74	1.75	49 49	11.68		49 49	3.3 3.3	-1.94 [-2.71, -1 -1.94 [-2.71, -1		•	
eterogeneity: not app	olicable								,		
st for overall effect:	Z = 4.91	P < 0.	0000	1)							
1.3. NDS _{14d}	5.93	2.58	33	7.55	2.27	30	3.2	162 282 0	421		
heng Mingxia 2014 an Yan 2014	11.48		41	18.29		40	3.0	-1.62 [-2.82, -0 -6.81 [-8.59, -5) • 2 2 2 2 • • 1 • 2 2 5 5 •
ing Ke 2012	13.01	4.25	35	15.64		35	3.1	-2.63 [-4.16, -1	.10]	-	> + + + + + + + + + + + + + + + + + +
o Yan 2016 o Xiangdong 2011	6.3 5.02	1.3 3.3	67 30	14.2 7.03		67 30	3.4 3.1	-7.90 [-8.49, -7 -2.01 [-3.58, -0		· _	1011100 101100
iyang Juan 2017	9.2	3.7	56	13.5	4.1	56	3.1	-4.30 [-5.75, -2		-	505555
n Shan 2018	1.8	0.72	40	2.78		40	3.4	-0.98 [-1.53, -0		-	••••••• •••••••••••••••••••••••••••••
n Dan 2015 n Haijiao 2021	2.29 8.51	1.39 3.77	43	9.27 15.46	4.67 4.42	43	3.3 3.0	-6.98 [-7.93, -6 -6.95 [-8.69, -5		- -	10111100 101110
Yuan 2016	8.01	1.37	40	17.66	1.68	40	3.4	-9.65 [-10.32, -8	8.98]	-) • () () () () () () () () () () () () ()
n Wenlan 2018 ing Jiawen 2014	14.61 6.05	2.25 1.81	66 30	20.53 9.28		67 30	3.3 3.3	-5.92 [-6.81, -5 -3.23 [-4.21, -2		-	1●111100 1●11100
ing Juan 2020	13.57		53	16.39		53	3.2	-2.82 [-4.04, -1	.60]	-	000000
ing Sujie 2017	7.9	3.7	28	9.2		28	3.0	-1.30 [-3.02, 0.			100000
ng Hongyan 2020 ao Guangfeng 2012	7.62 6.72	2.26 4.15	40 56	10.75 10.26		36 40	3.2 2.8	-3.13 [-4.40, -1 -3.54 [-5.79, -1		<u> </u>	1 • 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
btotal (95% CI)	0.72		758	10.20		735	50.7	-4.38 [-6.03, -2	-	•	
terogeneity: tau ² =					5 (P < 0)).0000	()1); $I^2 =$	98%			
t for overall effect:	Z = 5.19	(P < 0)	0.000)1)							
.4. NDS _{15d} Xiaojuan 2020	11.54	4.15	41	13.27	3 73	41	3.0	-1.73 [-3.44, -0	021	_	9 6 5 5 5 6
ng Qingli 2015	4.9	1.05		9.31		50	3.4	-4.41 [-4.92, -3		+ ¹	
ototal (95% CI)			91			91	6.4	-3.20 [-5.81, -0.	.58]	•	
terogeneity: tau ² = 1				= 1 (P =	= 0.003); I ² =	88%				
t for overall effect: .	5 = 2.40	(P = 0).02)								
.5. NDS _{21d} 1g Zhe 2017	10.27	3.04	67	15.6	3.85	67	3.2	-5.33 [-6.50, -4	.16]	-	
ang Debo 2020	4.03	1.01		7.52	1.35	57	3.4	-3.49 [-3.93, -3		÷	0 0 0 0 0 0 0 0
btotal (95% CI)	1 40 .1.	2 0 0	124	1 (D		124	6.6	-4.33 [-6.12, -2.	2.53]	•	
terogeneity: tau ² = st for overall effect: .					0.004); 1 =	00%				
.6. NDS _{28d}				,							
u Jiyu 2016	5.12			6.15		48	3.4	-1.03 [-1.55, -0		~) @ () () ()
n Yongqing 2020	3.84	0.51		5.79	0.62	42 90	3.4	-1.95 [-2.19, -1			> ⊕ 5 5 5 5 5 6 6 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 7 8 7
<i>ototal (95% CI)</i> terogeneity: tau ² = (0.38: chi	$i^2 = 9.9$	91 95. df	= 1 (P =	= 0.002		6.8 90%	-1.52 [-2.42, -0.	.02]	•	
t for overall effect:						,.					
.7. NDS _{30d}											
Yaozhong 2017 1 Shan 2018	10.27 1.6		56 40	13.64 2.38		52 40	3.2 3.4	-3.37 [-4.56, -2 -0.78 [-1.23, -0		- <u>-</u>) () () () () () () () () () () () () () ()
ng Qiuru 2017		1.12		16.54		44	3.4	-3.18 [-3.68, -2		+]	
ototal (95% CI)			138	c		136	10.0	-2.41 [-4.26, -0.	.55]	•	
erogeneity: tau ² = ; t for overall effect: .				f = 2 (P)	< 0.00	001);	1 ² = 969	6			
.8. NDS _{56d}	2 = 2.94	(1 – U									
Wei 2018	13.1	2.3	40	14.3	2.2	40	3.3	-1.20 [-2.19, -0	0.21]	-	••••••• •••••••••••••••••••••••••••••
ototal (95% CI)			40			40	3.3	-1.20 [-2.19, -0.		•	
		(D 7	102								
	2.38	(<i>r</i> ' = 0	,.02)								
t for overall effect:		3.12	52	10.59		52	3.2	-2.24 [-3.58, -0	.90]		••••••
t for overall effect:	8.35	2.17	48	10.59		48	3.3	-2.24 [-3.30, -1	.18]	<u>-</u>]	9 • • • • • • •
t for overall effect: . 9. NDS _{3m} ng Yihong 2019 ng Rong 2016	8.35 8.35	3.17	100	-1(D-		100 1 ² - 1	6.4 0%	-2.24 [-3.07, -1	.41]	•	
t for overall effect: . .9. NDS _{3m} .ng Yihong 2019 ang Rong 2016 <i>btotal (95% CI)</i>	8.35		0 44		- 1.00);	1 -	0 /0				
t for overall effect: . .9. NDS _{3m} ng Yihong 2019 ang Rong 2016 <i>ototal (95% CI)</i> terogeneity: tau ² = 0	8.35 0.00; chi	$i^2 = 0.0$)1)			100.0	-3.36 [-4.20, -2	2.531		
t for overall effect: . 9. NDS _{3m} ng Yihong 2019 ang Rong 2016 <i>ototal</i> (95% CI) terogeneity: $tau^2 = 0$ t for overall effect: . <i>al</i> (95% CI)	8.35 0.00; chi Z = 5.27	$i^2 = 0.0$ V(P < 0)	0.000 1464								
t for overall effect: . .9. NDS _{3m} ng Yihong 2019 ang Rong 2016 <i>ototal</i> (95% <i>CI</i>) terogeneity: tau ² = (t for overall effect: . <i>al</i> (95% <i>CI</i>) terogeneity: tau ² = :	8.35 0.00; chi Z = 5.27 5.26; chi	$i^2 = 0.0$ V(P < 0) $i^2 = 120$	0.0000 1464 09.50	df = 30						10 5 0 5 10	
ti for overall effect: . 9. NDS _{3m} ing Yihong 2019 ang Rong 2016 bitotal (95% CI) terogeneity: tau ² = (ti for overall effect: . val (95% CI) terogeneity: tau ² = . ti for overall effect: .	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90	$i^2 = 0.0$ i (P < 0) $i^2 = 120$ i (P < 0)).000 1464 09.50).000	, d <i>f</i> = 30) (P < 0).0000	(1); $I^2 =$	98%	_	-10 -5 0 5 10 PNS + CTs CTs	
st for overall effect: . .9. NDS $_{3m}$ ung Yihong 2019 ang Rong 2016 btotal (95% CI) terogeneity: tau ² = ! tf or overall effect: . tal (95% CI) terogeneity: tau ² = ! tf or overall effect: . st for overall effect: .	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90	$i^2 = 0.0$ i (P < 0) $i^2 = 120$ i (P < 0)).000 1464 09.50).000	, d <i>f</i> = 30) (P < 0).0000	(1); $I^2 =$	98%	_	-10 -5 0 5 10 PNS + CTs CTs	
terogeneity: not app st for overall effect: . .9. NDS _{3m} ang Yihong 2019 ang Rong 2016 <i>btotal</i> (95% <i>CI</i>) terogeneity: tau ² = ! st for overall effect: . <i>tal</i> (95% <i>CI</i>) terogeneity: tau ² = : st for overall effect: . st for subgroup diff sk of bias legend) Random sequence	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90 erences:	$i^{2} = 0.0$ i'(P < 0) $i^{2} = 120$ i'(P < 0) (P < 0) $chi^{2} = 0$	0.000 1464 09.50 0.000 31.37	df = 30 (01) df = 8	P < 0 (P = 0.)).0000	(1); $I^2 =$	98%	_		
st for overall effect: . .9. NDS $_{3m}$ ung Yihong 2019 ang Rong 2016 btotal (95% CI) terogeneity: tau ² = / tf or overall effect: . tal (95% CI) terogeneity: tau ² = / tf or overall effect: . st for subgroup diffect: st for subgroup diffect k of bias legend) Random sequenced Allocation conceal	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90 erences: : generat ment (s	$i^{2} = 0.0$ i' (P < 0) $i^{2} = 120$ i' (P < 0) $chi^{2} =$ tion (so electio	0.0000 1464 09.50 0.0000 31.37 electi on bia	df = 30 (01) df = 8 (01) df = 8 (01) df = 8 (01) df = 8 (01) df = 8 (01) df = 30	(P < 0) (P = 0.)	0.0000 .0001	01); I ² =	98%	_		
st for overall effect: . .9. NDS $_{3m}$ ung Yihong 2019 ang Rong 2016 btotal (95% CI) terogeneity: tau ² = ! tf or overall effect: . tal (95% CI) terogeneity: tau ² = ! st for overall effect: . st for overall effect: . ts for subgroup diffe sk of bias legend) Random sequence 0 Allocation conceal b Blinding of partici	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90 erences: generat ment (s pants ar	$i^{2} = 0.0$ i' (P < 0) $i^{2} = 120$ i' (P < 0) i' (P < 0) $chi^{2} =$ tion (so election ad person	0.0000 1464 09.50 0.0000 31.37 election bia	df = 30 $f, df = 8$ $f, df = 8$ on bias) $f, df = 8$	(P < 0) (P = 0)	0.0000 .0001	01); I ² =	98%	_		
tt for overall effect: . .9. NDS _{3m} ing Yihong 2019 ang Rong 2016 <i>btotal (95% CI)</i> terogeneity: $tau^2 = 1$ <i>it for overall effect: .</i> <i>it for overall effect: .</i> <i>it for overall effect: .</i> <i>it for overall effect: .</i> <i>it for subgroup diffe</i> <i>k of bias legend</i>) Random sequence Allocation conceal Blinding of partici) Blinding of outcor	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90 erences: e generat ment (spants ar ne asses	$i^{2} = 0.0$ $i' (P < 0)$ $i^{2} = 120$ $i' (P < 0)$ i	0.0000 1464 09.50 0.0000 31.37 electi on bia sonne (dete	df = 30 $f, df = 30$ $f, df = 8$ on bias $f, df = 8$	(P < 0) (P = 0)	0.0000 .0001	01); I ² =	98%	_		
st for overall effect: . .9. NDS $_{3m}$ ung Yihong 2019 ang Rong 2016 btotal (95% CI) terogeneity: tau ² = / tf or overall effect: . tal (95% CI) terogeneity: tau ² = / tf or overall effect: . st for subgroup diffect: st for subgroup diffect k of bias legend) Random sequenced Allocation conceal	8.35 0.00; chi Z = 5.27 5.26; chi Z = 7.90 erences: e generat ment (s pants ar ne asses ne data ($i^{2} = 0.0$ i' (P < 0) $i^{2} = 120$ i' (P < 0) $chi^{2} = 120$ $chi^{2} = 120$	0.0000 1464 09.50 0.0000 31.37 election bia sonna (deteon bia	df = 30 $f, df = 30$ $f, df = 8$ on bias $f, df = 8$	(P < 0) (P = 0)	0.0000 .0001	01); I ² =	98%	_		

FIGURE 4: Neurologic deficit score: PNS plus CTs vs. CTs.

of two studies, with dimensions of 43.6 and 43.4° north latitude, respectively, far north of the other three cities Xi'an, Shanghai, and Nanning. We considered that this was related to the influence of regional climate on blood viscosity, which will be further explored

in the future. The two studies were removed, and the other three studies were pooled alone (MD = 12.98, 95% CI = 11.65 to 14.31, P < 0.00001; Figure 7). Heterogeneity between the three studies was insignificant ($I^2 = 1\%$, P = 0.36).

Study or subgroup		JS + C			CTs		Weight		Mean difference	Risk of bias
Study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI	ABCDEFG
8.1.1. CSS _{14d}										
Han Yan 2014	11.48	3.47	41	18.29	4.62	40	24.8	-6.81 [-8.59, -5.03]	_ _	2 - 2 2 2 5 -
Jiang Ke 2012	13.01	4.25	35	15.64	1.78	35	25.2	-2.63 [-4.16, -1.10]		? + ? ? ? ? +
Su Yuan 2016	8.01	1.37	40	17.66	1.68	40	26.0	-9.65 [-10.32, -8.98]	+	? + ? ? ? ? +
Zhao Guangfeng 2012	6.72	4.15	56	10.26	6.37	40	24.0	-3.54 [-5.79, -1.29]		2 + 2 2
Subtotal (95% CI)			172			155	100.0	-5.71 [-9.55, -1.87]		
Heterogeneity: $tau^2 = 1$ Test for overall effect: 2				df = 3 (1)	P < 0.0)0001);	$I^2 = 97^{\circ}$	%		
8.1.2. NIHSS _{14d}										
Cheng Mingxia 2014	5.93	2.58	33	7.55	2.27	30	8.4	-1.62 [-2.82, -0.42]		2 • • • • • • • • •
Jiao Yan 2016	6.3	1.3	67	14.2	2.1	67	8.6	-7.90 [-8.49, -7.31]	-	3 + 5 5 5 +
Luo Xiangdong 2011	5.02	3.3	30	7.03	2.89	30	8.1	-2.01 [-3.58, -0.44]	_ 	2 + 5 2 5 5 +
Ouyang Juan 2017	9.2	3.7	56	13.5	4.1	56	8.2	-4.30 [-5.75, -2.85]		9 + 5 5 5 5
Ren Shan 2018	1.8	0.72	40	2.78	1.62	40	8.6	-0.98 [-1.53, -0.43]	+	? + ? ? ? ? +
Sun Dan 2015	2.29	1.39	100	9.27	4.67	100	8.5	-6.98 [-7.93, -6.03]	-	? + ? ? ? ? +
Sun Haijiao 2021	8.51	3.77	43	15.46	4.42	43	8.0	-6.95 [-8.69, -5.21]		? + ? ? ? ? ? ?
Tan Wenlan 2018	14.61	2.25	66	20.53	2.92	67	8.5	-5.92 [-6.81, -5.03]		? + ? ? ? ? +
Wang Jiawen 2014	6.05		30	9.28		30	8.5	-3.23 [-4.21, -2.25]	-	$2 \oplus 2 2 2 2 2$
Wang Juan 2020	13.57		53	16.39		53	8.3	-2.82 [-4.04, -1.60]		? + ? ? ? ? +
Wang Sujie 2017	7.9	3.7	28	9.2	2.8	28	8.0	-1.30 [-3.02, 0.42]		? + ? ? ? ? +
Yang Hongyan 2020	7.62	2.26	40	10.75	3.25	36	8.3	-3.13 [-4.40, -1.86]		? + ? ? ? ? ? ?
Subtotal (95% CI)			586			580	100.0	-3.94 [-5.65, -2.23]	•	
Heterogeneity: tau ² = 8	8.71; ch	$i^2 = 3i$	86.67, 0	df = 11	(P < 0	.00001); $I^2 = 92$	7%		
Test for overall effect: 2	Z = 4.52	2 (P <	0.0000	1)						
Test for subgroup diffe	rences:	chi ² =	= 0.68, 0	df = 1 (.	P=0.4	41), <i>I</i> ²	= 0%			
Risk of bias legend								-	-10 -5 0 5	10
(A) Random sequence		tion (alactic	n hiac)					PNS + CTs CTs	
B) Allocation conceal	0			,						
C) Blinding of partici					rman	e hiae				
(D) Blinding of outcor						<i>c</i> 0145,				
(E) Incomplete outcon					u3)					
(F) Selective reporting				,						
(G) Other bias	(report									

FIGURE 5: NIHSS and CSS at 14 days: PNS plus CTs vs. CTs.


3.4.4. ORR. There are thirty-seven studies that reported the overall response rate. Among them, thirty-two studies adopted the clinical efficacy scoring standard developed by the fourth national cerebrovascular conference in China in 1998, in which there are also four evaluation criteria for functional recovery. Subgroup analysis was performed according to different evaluation criteria. The heterogeneities of the NIHSS group and CSS group were not obvious $(I_{NIHSS}^2 = 0\%, P = 0.99; I^2CSS = 0\%, P = 0.75)$, so the fixed-effects model was used. The results demonstrated that the ORR for the PNS plus CTs was significantly higher than that of CTs alone $(RR_{NIHSS} = 1.20, 95\% CI = 1.16, to 1.24, P < 0.0001; RR_{CSS} = 1.15, 95\% CI = 1.08, to 1.24, P < 0.0001; Figure 8). There was no significant difference in the other two studies [45, 59] with the score of MESS and ADL.$

3.4.5. Hemorheology. A total of fourteen studies reported hemorheological parameters, including eleven [24, 25, 27, 28, 34, 37, 39, 44, 55, 56] for whole blood high shear viscosity (WBHSV), ten [20, 24, 25, 27, 28, 34, 37, 39, 44, 49] for whole blood low shear viscosity (WBLSV), ten [20, 24, 25, 27, 28, 37, 39, 49, 55, 56] for plasma viscosity (PV), and eight [20, 24, 28, 37, 39, 44, 48, 49] for fibrinogen (FIB). The

heterogeneities between the studies were large $(I^2_{WBHSV} = 93\%, P < 0.00001; I^2_{WBHSV} = 94\%, P < 0.00001; I^2_{PV} = 98\%, P < 0.00001; I^2_{FIB} = 92\%, P < 0.00001)$, and the heterogeneities still existed after subgroup analysis according to the course of treatment, dose, and dosage form. No other obvious sources of heterogeneities were found in sensitivity analysis, so descriptive analysis was used. See Figure 9 for results. Except for four studies [27, 37, 44, 48], the differences were statistically significant. The results showed that PNS plus CTs can effectively improve the hemorheology of patients with acute cerebral infarction.

3.4.6. MPAR. Two studies [28, 46] were assessed for the MPAR after patients had been treated. The results demonstrated that PNS plus CTs showed a weighty decrease on the MPAR compared with CTs alone (MD = -6.82, 95% CI = -9.62 to -4.02, P < 0.00001; Figure 10). The heterogeneity among the two studies was insignificant ($I^2 = 2\%$, P = 0.31), and a fixed-effects model was used.

3.4.7. Platelet Parameters. A total of four studies measured platelet parameters, including four [27, 39, 46, 48] for platelet count (PLT), two [27, 46] for mean platelet volume



(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

FIGURE 6: ADL-Barthel score: PNS plus CTs vs. CTs.

]	PNS + (CTs		CTs		Weight	Mean difference		Mean diff	erence	Risk of bias
Study or subgroup	Mean			Mean		Total	0	IV, random, 95% C	Ι	IV, random	, 95% CI	ABCDEFG
3.1.1. BI _{10d}												
Zhang Xin 2020	87.31	6.79	49	82.45	6.74	49	100.0	4.86 [2.18, 7.54]			-	? + ? ? ? ? +
Subtotal (95% CI)			49			49	100.0	4.86 [2.18, 7.54]			•	
Heterogeneity: not ap	plicable	2										
Test for overall effect:	Z = 3.5	6 (P = 0)	0.0004)								
3.1.2. BI _{14d}												
Jiao Yan 2016	83.2	10.5	67	66.5	7.3	67	0.0	16.70 [13.64, 19.76]				? + ? ? ? ? +
Li Naixia 2014	77.3	19.2	34	66.5		34	2.3	10.80 [2.09, 19.51]				(+) () () () () () () () () (
Tan Wenlan 2018	61.32	15.77	66	51.91		67	5.8	9.41 [3.89, 14.93]	_			? + ? ? ? ? ? +
Yang Hongyan 2020	86.78	3.12	40	73.52		36	91.9	13.26 [11.99, 14.53]				$\mathbf{\widehat{)}} \oplus \mathbf{\widehat{)}} \mathbf{\widehat{)}} \mathbf{\widehat{)}} \mathbf{\widehat{)}} \mathbf{\widehat{)}}$
Zhang Li 2020	67.54	16.38	50	50.53	15.42	50	0.0	17.01 [10.77, 23.25]				? + ? ? ? ? ? ?
Subtotal (95% CI)			140			137	100.0	12.98 [11.65, 14.31]]		•	
Heterogeneity: tau ² =					0.36)	; $I^2 = 1$	%					
Test for overall effect:	Z = 19.	08 (P <	0.000	01)								
3.1.3. BI _{28d} Gou Jiyu 2016	77 69	16.38	48	70.53	16 / 1	48	100.0	7.16 [0.06, 13.72]				5 1 2 2 2 2 2 1
Subtotal (95% CI)	//.07	10.50	48	70.55	10.41		100.0	7.16 [0.06, 13.72]				
			48			48	100.0	7.10 [0.00, 13.72]				
Heterogeneity: not ap	-								1		I	
Test for overall effect:	Z = 2.1	4(P = 0)).03)						-20	-10 0	10	20
Risk of bias legend										CTs	PNS + CTs	
(A) Random sequenc	e genera	ation (s	electio	on bias)								
(B) Allocation concea	0											
(C) Blinding of partic				·	manc	e bias)						

(C) Blinding of participants and personnel (performation) (D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

FIGURE 7: ADL-Barthel score (sensitivity analysis): PNS plus CTs vs. CTs.

	PNS -	+ CTs	C	Ts	Weight	Risk Ratio	Risk	Ratio	Risk of bias
Study or subgroup	Events	Total	Events	Total	(%)	M-H, fixed, 95% CI		ed, 95% CI	ABCDEFG
1.1.1. ORR _(NIHSS)									
Cheng Mingxia 2014	31	32	24	30	2.8	1.21 [1.00, 1.46]			8 8 8 9 8 9 9
Chen Jie 2018	23	25	16	25	1.8	1.44 [1.05, 1.97]			? 1 ? ? ? ? ? 1
Feng Zhe 2017	64	67	56	67	6.4	1.14 [1.02, 1.29]			5 + 5 5 5 5 5
Gou Jiyu 2016	45	48	38	48	4.4	1.18 [1.01, 1.39]			
Huang Debo 2020 Huang Yuan 2016	55 60	57 62	47 50	57 62	5.4 5.7	1.17 [1.03, 1.33] 1.20 [1.05, 1.37]			
Hu Yaozhong 2017	49	56	30	52	4.4	1.23 [1.01, 1.50]			
Jiao Yan 2016	64	67	56	67	6.4	1.14 [1.02, 1.29]			
Luo Xiangdong 2011	28	30	21	30	2.4	1.33 [1.04, 1.72]			6 6 6 6 6 6 6 6
Ouyang Juan 2017	51	56	42	56	4.8	1.21 [1.02, 1.44]			
Sun Dan 2015	97	100	87	100	10.0	1.11 [1.03, 1.21]			5 1 2 3 2 4 1
Sun Haijiao 2021	40	43	32	43	3.7	1.25 [1.03, 1.52]			5 • 5 5 5 5 5
Tan Wenlan 2018	52 41	66 43	42 35	67 42	4.8 4.1	1.26 [1.01, 1.57]			
Tian Yongqing 2020 Wang Jiawen 2014	41 29	45 30	25	42 30	4.1 2.9	1.14 [0.98, 1.33] 1.16 [0.98, 1.38]			2 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Wang Juan 2020	50	53	42	53	4.8	1.19 [1.02, 1.39]			
Wang Yihong 2019	47	52	39	52	4.5	1.21 [1.01, 1.44]			
Wei Dongsheng 2017	28	30	24	30	2.8	1.17 [0.95, 1.43]	-		6 6 7 6 7 6 6
Xiao Shuhong 2020	37	39	28	39	3.2	1.32 [1.07, 1.63]			6 0 2 2 2 0 0 0
Xu Zhimin 2020	33	35	27	35	3.1	1.22 [1.00, 1.49]		<u> </u>	? 1 ? ? ? ? ? 1
Yang Hongyan 2020	36	40	26	36	3.1	1.25 [0.99, 1.56]			5 0 2 2 2 2 2 2 2 2
Zeng Qingli 2015	46	50	35	50	4.0	1.31 [1.08, 1.60]			8 4 5 5 5 9 4
Zhang Rong 2016	44	48	37	48	4.3	1.19 [1.00, 1.42]			?
Subtotal (95% CI)		1129		1119	100.0	1.20 [1.16, 1.24]		♦	
Total events	1050		866						
Heterogeneity: $chi^2 = 9.35$, $df =$			0%						
Test for overall effect: $Z = 10.2$	5 (P < 0.00)	001)							
1.1.2. ORR _(CSS)									
Han Yan 2014	39	41	33	40	15.4	1.15 [0.98, 1.35]			
Jiang Ke 2012	31	35	28	35	12.9	1.11 [0.90, 1.36]	_		
Su Yuan 2016	36	40	29	40	13.3	1.24 [1.00, 1.54]			
Tang Duyong 2014	19	21	16	21	7.4	1.19 [0.90, 1.57]			6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
Wang Liying 2013	62	65	37	45	20.1	1.16 [1.00, 1.34]			? + ? ? ? ? ? ?
Yu Yongcai 2014	32	34	31	34	14.3	1.03 [0.90, 1.18]	_	-	5 🖶 5 5 5 5 5
Zhao Guangfeng 2012	52	56	31	40	16.6	1.20 [1.00, 1.44]			5 1 2 2 2 2 2 2
Subtotal (95% CI)		292		255	100.0	1.15 [1.08, 1.24]		•	
Total events	271		205						
Heterogeneity: $chi^2 = 3.43$, df Test for overall effect: $Z = 4.06$)%						
112 OPP									
1.1.3. ORR _(MESS)									
Li Naixia 2014	28	34	22	34	100.0	1.27 [0.95, 1.71]	-		2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Subtotal (95% CI)		34		34	100.0	1.27 [0.95, 1.71]	-		
Total events	28		22						
Heterogeneity: not applicable Test for overall effect: $Z = 1.61$	(P = 0.11)								
	,								
1.1.4. ORR _(ADL)									
Li Chang 2013	29	36	27	36	100.0	1.07 [0.84, 1.38]			? 1 ? ? ? ? ? ?
Subtotal (95% CI)		36		36	100.0	1.07 [0.84, 1.38]			
Total events	29		27						
Heterogeneity: not applicable Test for overall effect: $Z = 0.57$	(P = 0.57)								
Risk of bias legend (A) Random sequence generat (B) Allocation concealment (s (C) Blinding of participants ar (D) Blinding of outcome asses	tion (selecti election bia 1d personne	as) el (perfoi		as)					
(E) Incomplete outcome data								H 1 1	_
(L) meompiete outcome duta								1 15 2	
(F) Selective reporting (report (G) Other bias							0.5 0.7 CTs	1 1.5 2 PNS + CTs	2

FIGURE 8: ORR: PNS plus CTs vs. CTs.

(MPV), and two [27, 46] for platelet distribution width (PDW). Since the result of one study [39] was contrary to the conclusion, PLT was finally included in three studies. The results demonstrated that PNS plus CTs was better than CTs in improving PLT (MD_{PLT} =4.85, 95% *CI*=1.82 to 7.84, P = 0.002; Figure 11) and reducing MPV (MD_{MPV} =-0.79, 95% *CI*=-1.09 to -0.48, P < 0.00001; Figure 12). The heterogeneity among studies was insignificant (I^2_{PLT} =0%, P = 1.00; I^2_{MPV} =36%, P = 0.21), and a fixed-effects model was used. In addition, the differences were not statistically


significant in changing PDW ($MD_{PDW} = -0.01$, 95% CI = -0.31 to 0.30, P = 0.97; Figure 12).

3.4.8. CD62P. Two studies [47, 48] were assessed for the CD62P, one of which observed serum CD62P and platelet membrane CD62P, and the other only observed platelet membrane CD62P. The results of the two studies were positive, but the combined confidence interval included zero (SMD = -2.08, 95% CI = -4.95 to 0.80, P = 0.16; Figure 13).

Study or subgroup		PNS + C	Ts		CTs		Weight	Mean difference	Mean difference	Risk of bias
study of subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI	ABCDEFG
4.1.1. WBHSV										
Chen Jie 2018	5.94	1.02	25	6.5	0.92	25	7.9	-0.56 [-1.10, -0.02]		
Gou Jiyu 2016	4.18	0.54	48	4.78	0.55	48	9.6	-0.60 [-0.82, -0.38]	-	
Huang Yuan 2016	5.18	1.09	62	6.24	1.05	62	8.8	-1.06 [-1.44, -0.68]	-	
Hu Yaozhong 2017	6.03	1.18	56	6.75	0.89	52 90	8.8 9.7	-0.72 [-1.11, -0.33]		
Sun Qiaoshu 2019	6.24 4.17	0.62 0.55	96 30	6.86 4.79	0.68 0.54	90 30	9.7	-0.62 [-0.81, -0.43] -0.62 [-0.90, -0.34]	T	5 + 5 5 5 5 +
Wei Dongsheng 2017 Xiao Jun 2020	4.17	0.55	50 65	4.79 5.13	0.54 1.41	50 65	9.5 8.6	-0.44 [-0.86, -0.02]		5 + 5 5 5 5 + 5 + 5 5 5 +
Xiao Shuhong 2020	4.53	0.68	39	5.61	0.94	39	8.9	-1.08 [-1.44, -0.72]		
Xu Zhimin 2020	5.54	0.41	35	6.32	0.42	35	9.7	-0.78 [-0.97, -0.59]		
Yu Yongcai 2014	5.53	0.77	34	5.81	0.25	34	9.4	-0.28 [-0.55, -0.01]		
Zeng Qingli 2015	3.79	0.78	50	6.1	0.61	50	9.4	-2.31 [-2.58, -2.04]	-	
Subtotal (95% CI)			540			530	100.0	-0.83 [-1.16, -0.50]		••••••
Heterogeneity: $tau^2 = 0.28$ Test for overall effect: $Z =$			= 10 (P	< 0.0000	01); I ² =		100.0	0.05 [1.10, 0.50]	•	
4.1.2. WBLSV										
Chen Jie 2018	10.34	1.35	25	11.29	1.85	25	9.9	-0.95 [-1.85, -0.05]		? • ? ? ? ? • ?
Huang Yuan 2016	12.8	1.92	62	14.62	2.09	62	10.3	-1.82 [-2.53, -1.11]	—	
Hu Yaozhong 2017	7.58	1.09	56	8.86	1.25	52	10.8	-1.28 [-1.72, -0.84]		
Sun Qiaoshu 2019	11.61	1.35	96	12.07	1.42	90	10.9	-0.46 [-0.86, -0.06]		
Vang Liying 2013	8.11	2.49	65	9.84	3.15	45	9.3	-1.73 [-2.83, -0.63]		5 6 5 5 5 5 5
Kiao Jun 2020	9.45	1.54	65	10.37	2.68	65	10.2 10.3	-0.92 [-1.67, -0.17]		
Kiao Shuhong 2020 Ku Zhimin 2020	9.64 11.23	1.37 2.24	39 35	11.9 12.87	1.86 2.72	39 35	9.2	-2.26 [-2.99, -1.53] -1.64 [-2.81, -0.47]		5 + 5 5 5 5 + 5 + 5 5 5 +
lu Yongcai 2014	11.23	2.24	34	12.37	3.58	34	8.0	-1.04 [-2.61, 0.53]		
Zeng Qingli 2015	7.71	0.82	50	11.24	0.96	50	11.0	-3.53 [-3.88, -3.18]		
Subtotal (95% CI)	7.71	0.02	527	11.21	0.90	497	100.0	-1.58 [-2.41, -0.75]		
Heterogeneity: $tau^2 = 1.62$ Fest for overall effect: $Z =$				< 0.0000	1); I ² =		100.0	1.50 [2.11, 0.75]	•	
4.1.3. PV										
Chen Jie 2018	1.38	0.26	25	1.93	0.34	25	9.6	-0.55 [-0.72, -0.38]	-	
Gou Jiyu 2016	0.76	0.15	48	1.21	0.13	48	10.8	-0.45 [-0.51, -0.39]	•	5 9 5 5 5 9
Huang Yuan 2016	1.4 1.56	1.05 0.12	62 96	1.48 1.59	1.02 0.13	62 90	6.6 10.9	-0.08 [-0.44, 0.28]	-	
Sun Qiaoshu 2019 Wang Liying 2013	1.56	0.12	96 65	2.01	0.15	90 45	10.9	-0.03 [-0.07, 0.01] -0.39 [-0.53, -0.25]	I	2 + 5 2 2 5 -
Wei Dongsheng 2017	0.75	0.35	30	1.2	0.38	30	10.0	-0.45 [-0.53, -0.37]		
Xiao Jun 2020	1.29	0.07	65	1.55	0.09	65	10.7	-0.26 [-0.29, -0.23]		
Xiao Shuhong 2020	1.26	0.14	39	1.64	0.21	39	10.6	-0.38 [-0.46, -0.30]		
Ku Zhimin 2020	1.94	0.42	35	2.58	0.44	35	9.1	-0.64 [-0.84, -0.44]		
Zeng Qingli 2015	1.2	0.13	50	1.9	0.16	50	10.8	-0.70 [-0.76, -0.64]		
Subtotal (95% CI)			515			489	100.0	-0.40 [-0.55, -0.25]		•••••
Heterogeneity: tau ² = 0.05	5; $chi^2 = 4$	79.67, dj	010	< 0.0000	1); $I^2 =$		100.0	-0.40 [-0.55, -0.25]	•	
Test for overall effect: $Z =$										
.1.4. FIB	2.24	0.75	25	4.96	1.20	25	10.5	1.52[2.10 0.04]		
Chen Jie 2018 Juang Yuan 2016	3.34 2.58	0.75 1.08	25 62	4.86 3.27	1.28 1.92	25 62	10.5 10.9	-1.52 [-2.10, -0.94]		
Huang Yuan 2016 Wang Liying 2013	2.58	0.31	62 65	3.27 3.92	0.37	62 45	10.9 14.4	-0.69 [-1.24, -0.14] -1.15 [-1.28, -1.02]		
Vang Liying 2013 Kiao Shuhong 2020	3.47	0.31	65 39	3.92 4.85	1.29	45 39	14.4 11.6	-1.15 [-1.28, -1.02] -1.38 [-1.86, -0.90]		<pre> 5 + 5 5 5 5 5 5 </pre>
Ku Zhimin 2020	3.14	0.85	35	4.85 3.67	0.52	35	13.9	-0.53 [-0.75, -0.31]	* <u>+</u>	
lang Chengzhi 2013	3.14	0.43	30	3.28	0.52	30	13.9	-0.04 [-0.29, 0.21]		
Yu Yongcai 2014	3.49	1.07	34	3.77	1.24	34	10.8	-0.28 [-0.83, 0.27]		
Zeng Qingli 2015	3.29	0.37	50	4.5	0.53	50	14.2	-1.21 [-1.39, -1.03]	+	
Subtotal (95% CI))3.24, df =	340); I ² = 9	320	100.0	-0.84 [-1.19, -0.49]	•	
Heterogeneity: tau ² = 0.22										
Heterogeneity: $tau^2 = 0.22$ Test for overall effect: $Z =$ Risk of bias legend		(a.1	. h:							
Fest for overall effect: Z = Risk of bias legend A) Random sequence ge	neration		n bias)							
Test for overall effect: Z = Risk of bias legend (A) Random sequence ge (B) Allocation concealme	neration ent (select	ion bias)		nance hi	20)			-4	-2 0 2	4
'est for overall effect: Z = Lisk of bias legend A) Random sequence ge	neration ent (select nts and pe	ion bias) ersonnel	(perforr		as)			-4	-2 0 2 PNS + CTs CTs	4

(F) Selective reporting (reporting bias)

(G) Other bias



The heterogeneity between the two studies was significant ($I^2 = 98\%$, P < 0.00001), so a random-effects model was used. After rereading the full text to verify the extracted data and find the reason for the heterogeneity, we considered the heterogeneity resulting from different units. Although both studies indicated that the tool for measuring platelet membrane CD62P was flow cytometry, the data results showed that the observation value of one study was concentration and the observation value of the other study was expression rate. No significant clinical heterogeneity was found between the two studies. Since the units of the same outcome are different and cannot be converted, *SMD* was

used for consolidation. In addition, the serum CD62P observed in one study showed that PNS + CTs decreased more than CTs (MD = -0.21, 95% CI = -0.29 to -0.13, P < 0.00001; Figure 14).


3.4.9. Coagulation Function. Two studies [39, 48] assessed the coagulation function. The heterogeneity among the two studies was significant ($I^2 = 91\%$, P = 0.001), and a random-effects model was used. In the prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), there was no statistical difference between the

Study or subgroup		S + C SD		Mean	CTs SD	Total	Weight (%)	Mean difference IV, fixed, 95% CI		difference d, 95% CI	Risk of bias A B C D E F G
Cheng Mingxia 2014 Chen Jie 2018 Total (95% CI)	4 37.82 34.39		33 25 58	43.76 43.59		30 25 55	73.1 26.9 100.0	-5.94 [-9.21, -2.67] -9.20 [-14.60, -3.80] -6.82 [-9.62, -4.02]	-		<pre> ?</pre>
Heterogeneity: chi^2 Test for overall effect			P = 0.3	· ·	2%	55	100.0		10 0	0 5 10	_
Risk of bias legend									PNS + CTs	CTs	
(A) Random sequen(B) Allocation conce	0				s)						
(C) Blinding of particular(D) Blinding of outcome	ome asse	essme	nt (det	ection l		nce bia	s)				

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias



(F) Selective reporting (reporting bias)

(G) Other bias

FIGURE 11: PLT: PNS plus CTs vs. CTs.

Study or subgroup		NS + C		M	CTs	T-4-1	Weight		Mean difference	Risk of bias
	Mean	SD	Iotal	Mean	SD	Total	(%)	IV, fixed, 95% CI	IV, fixed, 95% CI	ABCDEFG
7.1.2. MPV		0.05	22	10.0	1.16	20	22.2	106[150_052]		
Cheng Mingxia 2014				12.3		30	33.3	-1.06 [-1.59, -0.53]		
Sun Qiaoshu 2019	8.02	1.31		8.67	1.28	90	66.7	-0.65 [-1.02, -0.28]		? ① ? ? ? ?]
Subtotal (95% CI)			129			120	100.0	-0.79 [-1.09, -0.48]	•	
Heterogeneity: chi ²		2	·		36%					
Test for overall effect	t: $Z = 5$.	07 (P ·	< 0.000	01)						
7.1.3. PDW										
Cheng Mingxia 2014	4 14.23	2.29	33	15.87	2.66	30	6.1	-1.64 [-2.87, -0.41]		5 🖶 5 5 5 6
Sun Qiaoshu 2019	16.9	1.17	96	16.8	1.02	90	93.9	0.10 [-0.21, 0.41]		2 + 2 2 5 5 +
Subtotal (95% CI)			129			120	100.0	-0.01 [-0.31, 0.30]	▲	
Heterogeneity: chi2	= 7.20, c	df = 1	(P = 0.0)	007); I ²	= 86%	, D]	
Test for overall effect										
								-	-2 -1 0 1 2	
Test for subgroup di	fference	s: chi ²	² = 12.5	9, d <i>f</i> =	1 (P =	0.0004	I^{1} ; $I^{2} = 9$	2.1%	PNS + CTs CTs	
Risk of bias legend									FIN3 + C13 C13	
(A) Random sequen	ce gene	ration	(select	ion bias	;)					
(B) Allocation conce	U		·		- /					
(C) Blinding of parti				· ·	ormai	1ce bia	s)			
(D) Blinding of outc	1	-		· I			- /			
(E) Incomplete outc					,					
(F) Selective reportin										
(G) Other bias		0								

Study or subgroup	PN Mean	NS + C SD		Mean	CTs SD	Total	Weight (%)	Std. mean difference IV, random, 95% CI		Std. mean difference IV, random, 95% CI				Risk of bias A B C D E F G
Lu Xiaoping 2014 Yang Chengzhi 2013	2.52 25.69		64 30	2.68 48.41	0.27 6.22	64 30	50.9 49.1	-0.63 [-0.99, -0.28] -3.57 [-4.40, -2.74]		- 1				5 • 5 5 5 5 5 5 5 • 5 5 5 5 5
Total (95% CI)			94			94	100.0	-2.08 [-4.95, 0.80]						
Heterogeneity: tau ² = Test for overall effect Risk of bias legend		J (-4 PNS	-2 5 + CTs	0	2 CTs	4	-						
(A) Random sequend	e gene	ration	(select	ion bia	s)									
(B) Allocation conce	alment	(selec	tion bia	as)										
(C) Blinding of partie	cipants	and p	ersonn	el (perf	orma	nce bia	s)							
(D) Blinding of outco	ome ass	essme	ent (det	ection	bias)									
(E) Incomplete outco	me dat	a (attr	ition b	ias)										
(F) Selective reportin	ig (repo	orting	bias)											

(G) Other bias






FIGURE 14: Serum CD62P: PNS plus CTs vs. CTs.

two groups $(MD_{PT} = 0.93, 95\% CI = -0.75 \text{ to } 2.62, P = 0.28; MD_{TT} = -0.08, 95\% CI = -1.75 \text{ to } 1.59, P = 0.92; MD_{APTT} = -0.81, 95\% CI = -2.57 \text{ to } 0.95, P = 0.37; Figure 15).$

After sensitivity analysis and careful reading of the original literature, we found that the course of treatment between the two studies was different, which might be the major source of the heterogeneity.

3.5. Safety Outcomes

3.5.1. Incidence of Adverse Reactions. Eight studies [21, 32, 35, 52, 54–56, 61] recorded the incidence of adverse reactions. Incidence of adverse reactions occurred in 26 out of 315 patients (8.3%) who received PNS plus CTs and 42 out of 314 patients (13.4%) who received CTs alone. The heterogeneity among eight studies was insignificant ($I^2 = 0.0\%$, P = 0.45), and a fixed-effects model was used. The incidence of adverse reactions of the experimental group was lower than that of the control group (RR = 0.62, 95% CI = 0.39 to 0.97, P = 0.04; Figure 16).

3.5.2. Adverse Reactions. Fifteen studies [21, 29, 31, 32, 34, 35, 43, 44, 52, 54–58, 61] reported adverse reactions. Among them, six studies [29, 31, 34, 43, 44, 58] reported no adverse

reaction in both groups, and the other studies reported adverse reactions in two groups including gastrointestinal reactions, skin rashes, abnormal liver function, palpitation, infusion reaction, and other unexplained adverse reactions. No participants discontinued the study drug due to adverse reactions.

3.6. *Publication Bias.* The ORRNIHSS of twenty-three studies was evaluated by the funnel chart, and the results showed that the left-right asymmetry may be related to the low methodological quality and unpublished negative results of the included studies, as shown in Figure 17.

3.7. *GRADE Assessment.* The GRADE system was used to assess the level of evidence for the twelve outcomes, which indicated low or very low quality with serious methodological problems, a heterogeneity problem, and a small sample problem. The GRADE evidence profiles are shown in Supplementary File 5.

4. Discussion

4.1. Summary of Evidence. In the current systematic review, we evaluated the efficacy of Panax Notoginseng Saponins (PNS) including four types of Chinese medicine injection

	PNS + CTs						Weight	Mean difference	Mean difference	Risk of bias
Study or subgroup	Mean			Mean	CTs SD	Total	(%)	IV, random, 95% CI	IV, random, 95% CI	A B C D E F G
10.1.1 PT										
Yang Chengzhi 2013	11.82	1.48	30	11.75	1.46	30	49.8	0.07 [-0.67, 0.81]	+	$ \cdot $
Zeng Qingli 2015	14.83	2.07	50	14.04	1.52	50	50.2	1.79 [1.08, 2.50]		? + ? ? ? ? +
Subtotal (95% CI)			80			80	100.0	0.93 [-0.75, 2.62]		
Heterogeneity: tau ²	= 1.34, c	$hi^2 = 10$	0.72, d <i>f</i>	r = 1 (P = 1)	= 0.001); $I^2 = 9$	1%			
Test for overall effec	t: $Z = 1.0$	P = (P = 0.000)	0.28)							
10.1.2 TT										
Yang Chengzhi 2013	19.37	3.22	30	19.45	3.36	30	100.0	-0.08 [-1.75, 1.59]		$ \cdot $
Subtotal (95% CI)			30			30	100.0	-0.08 [-1.75, 1.59]	-	
Heterogeneity: Not a	applicabl	le								
Test for overall effec	t: $Z = 0.0$	P = (P = 0.00)	0.92)							
10.1.3 APTT										
Yang Chengzhi 2013	28.88	3.45	30	29.69	3.51	30	100.0	-0.81 [-2.57, 0.95]		$ \cdot $
Subtotal (95% CI)			30			30	100.0	-0.81 [-2.57, 0.95]		
Heterogeneity: Not a	applicabl	le								
Test for overall effec	t: $Z = 0.9$	90 (P =	0.37)							
										_
									-4 -2 0 -2 -4	
Test for subgroup di	fferences	s: chi ² =	= 1.99, (df = 2 (I	P = 0.3	7); $I^2 = 0$	0%		CTs PNS + CTs	
Risk of bias legend			,	5						
(A) Random sequen	ce gener	ration (electio	n bias)						
(A) Kallootian sequel	0									

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

FIGURE 15: Coagulation function: PNS plus CTs vs. CTs.

Study or subgroup	PNS +	CTs	СТ	ſs	Weight	Risk ratio	Risk ratio	Risk of bias
Study of subgroup	Events	Total	Events	Total	(%)	M-H, fixed, 95% CI	M-H, fixed, 95% CI	ABCDEFG
Gou Jiyu 2016	2	48	3	48	7.1	0.67 [0.12, 3.81]		? + ? ? ? ? +
Luo Xiangdong 2011	2	30	1	30	2.4	2.00 [0.19, 20.90]		? + ? ? ? ? +
Sun Haijiao 2021	1	43	7	43	16.7	0.14 [0.02, 1.11]		? + ? ? ? ? ? ?
Su Yuan 2016	3	40	5	40	11.9	0.60 [0.15, 2.34]		? + ? ? ? ? +
Tian Yongqing 2020	3	43	2	42	4.8	1.47 [0.26, 8.33]		
Wang Juan 2020	6	53	4	53	9.5	1.50 [0.45, 5.01]		9 + 9 9 9 9 +
Wang Sujie 2017	4	28	8	28	19.0	0.50 [0.17,1.47]		$\begin{array}{c} 0 \\ $
Wei Dongsheng 2017	5	30	12	30	28.6	0.42 [0.17, 1.04]		? < ? ? ? ?
Total (95% CI)		315		314	100.0	0.62 [0.39, 0.97]	•	
Total events	26		42					
Heterogeneity: $chi^2 = 0$	6.82, $df = f$	7 (P = 0.4)	45); $I^2 = 0$	%		0.0	1 0.1 1 10	100
Test for overall effect:	Z = 2.07 (1	P = 0.04))					
							PNS + CTs CTs	
Risk of bias legend								
(A) Random sequence	generatio	on (select	tion bias)					
(B) Allocation conceal	ment (sele	ection bi	as)					
(C) Blinding of partici	pants and	personn	el (perfor	mance b	ias)			
(D) Blinding of outcor	ne assessn	nent (det	tection bia	s)				
(E) Incomplete outcom	ne data (at	ttrition b	oias)					
(F) Selective reporting	(reportin	g bias)						
(G) Other bias								

FIGURE 16: Incidence of adverse reactions: PNS plus CTs vs. CTs.

and four types of oral Chinese patent medicine to treat patients with AIS. We conducted a comprehensive literature search and identified 43 RCTs (4170 participants) for analysis. Compared with CTs, PNS plus CTs was more effective in the treatment of patients with AIS, in increasing the proportion of patients with independent function after 3 months (only one small sample study), improving neurological function, and restoring activities of daily living. Over the past few years, pharmacological experiments found that PNS can increase the blood oxygen supply of ischemic tissue by maintaining the physiological function of mitochondria [62], promoting the proliferation of vascular endothelial




FIGURE 17: The funnel diagram of PNS plus CTs and CTs to compare ORRNIHSS.

cells [63], promoting angiogenesis [64], and improving hemorheology [65] in the treatment of cerebral ischemia.

For the laboratory outcomes, the results showed positive effects of PNS on improving WBHSV, WBLSV, PV, and FIB. In the aspect of antiplatelet effects, PNS can effectively reduce MPAR and MPV and increase PLT. However, there is insufficient evidence for PNS to inhibit the expression of CD62P and improve coagulation function. In surviving AIS patients, the reduction in platelet aggregation (PA) was accompanied by improvements in the clinical condition, whereas the negative dynamic of PA was recorded in deceased patients [66]. And Tsuyoshi Uesugi's study also found that the recurrence rate of ischemic stroke in patients with inhibition of PA after antiplatelet therapy was significantly lower than that in patients with unchanged PA [67]. Although platelet function testing may be of guiding significance in drug therapy to improve the prognosis of AIS, a study had shown that platelet function-guided modification in antiplatelet therapy after AIS was associated with significantly higher rates of adverse clinical outcomes [68]. The latest systematic review found that MPV was significantly higher and PLT was significantly lower in patients with ischemic stroke [69], so they may be used as markers to predict the recurrence of ischemic stroke. Nevertheless, Irene Ciancarelli's study provided that MPV was not a marker of neurologic deficit and disability or of stroke recovery including motor performance and functional independence and cannot be used to evaluate the prognosis of AIS [70].

For the safety outcomes, the results showed that the incidence of adverse reactions in the PNS group was lower than that in the CT group. The adverse reactions of the experimental group were mainly mild gastrointestinal discomfort and rash, which suggested that PNS should be used carefully in patients with chronic gastric disease and allergy history.

4.2. Strengths and Limitations. Compared with the previous reviews, the current systematic review is comprehensive and included 43 trials, which provides relatively complete and

up-to-date evidence on the use of PNS as adjunct therapies for AIS. We used an evidence-based medicine approach to critically review the existing evidence from previous RCTs, and we found a better effect of PNS for independent function, platelet parameters, and MPAR. In addition, we applied GRADE criteria to determine the certainty in the estimate of effect for important outcomes.

There are some limitations to our review that need to be acknowledged. Firstly, in the real world, various drugs are commonly used in the treatment of AIS. Although we strictly limited the drug category of CTs in the eligibility criteria, in our review, most of the trials did not mention the specific therapeutic regimen, which resulted in inevitable clinical heterogeneity to a certain extent. Furthermore, excessive statistical heterogeneity came to our attention in some of the comparisons. However, we cannot identify the source of heterogeneity through the data and information provided. The quality of the included trials is generally poor in random sequence generation and blind design, which is a common problem in the current situation of clinical trials of TCM [71]. In addition, the insufficient sample size of included studies in some comparisons affected the reliability of the results. Lastly, as some randomized, double-blind, controlled large-sample clinical trials are ongoing, such as the RCT of Xuesaitong soft capsules treating patients with AIS conducted by Xuanwu Hospital Capital Medical University, evidence from the current analysis is incomplete, and further updates are expected to complement the results of this systematic review.

4.3. Implications for Future Research. Long-term outcomes, such as 3-month favorable functional outcome, should be chosen as the primary outcome, instead of using intermediate outcomes to substitute for endpoint outcomes as many clinical trials of TCM [72]. The measurement time of various outcomes should be standardized [73] to ensure the data merging between different studies. NIHSS score is suggested to be used in evaluating the neurological deficit uniformly, in order to avoid the heterogeneity caused by different standards. It is hoped that more attention will be paid to the occurrence of bleeding events during the treatment of AIS, since the combination of antiplatelet drugs, anticoagulants, and PNS makes it difficult to evaluate the bidirectional regulation function only through laboratory indicators such as MPAR, MPV, and PT.

Future researchers are urged to design experiments based on a rigorous methodology, including appropriate sample sizes and adequate follow-up with long-term duration, and the standardized report will be carried out according to the guidelines of SPIRIT-TCM Extension 2018 [74] and CONSORT-CHM formulas 2017 [75]. In terms of safety analysis, researchers must assess whether the adverse events are related to drug use. And economic analysis should be considered to guide practices.

5. Conclusion

We found that PNS combined with CTs has a certain effect on the treatment of AIS. However, due to the small number of studies and the high risks of bias, the above evidence is low to very low and the safety remains uncertain. In the future, more strong evidence for clinical practice requires largescale and high-quality RCT.

Data Availability

The data used in the article are obtained from public databases. The processes including the literature, data extraction, and calculation are all described in the article. If necessary, the first author LDW (liudingwang97@163.com) can be contacted to obtain data.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

LDW and XL had the idea for the study design. LDW retrieved literature, selected the studies, extracted data, analyzed data, and wrote this manuscript. ZMX and WRQ selected the studies and extracted data. All authors contributed to the article and approved the submitted version.

Acknowledgments

The study was funded by the General Project of the National Natural Science Foundation of China (no. 81774159), 2019, the State Administration of Traditional Chinese Medicine TCM evidence-based capacity building project (no. ZZ13-024-3), and the National TCM Leading Personnel Support Program (NATCM Personnel and Education Department (2018)) (no. 12). The authors thank Philip Lee for proofreading the manuscript.

Supplementary Materials

Supplementary File 1. Table S1 containing search strategy. Supplementary File 2. Table S2 containing the list of excluded reports. Supplementary File 3. Table S3 containing the basic characteristics of included studies. Supplementary File 4. Table S4 containing the basic characteristics of PNS preparations. Supplementary File 5. Table S5 containing a GRADE summary of outcomes. Supplementary File 6. PRISMA 2020 checklist. Supplementary File 7. Research protocol. (Supplementary Materials)

References

- [1] X. Peng, Y. Wan, W. Liu et al., "Protective roles of intraarterial mild hypothermia and arterial thrombolysis in acute cerebral infarction," *Springer Plus*, vol. 5, no. 1, 2016.
- [2] Y.-N. You, M.-R. Cho, J.-H. Kim et al., "Assessing the quality of reports about randomized controlled trials of scalp acupuncture combined with another treatment for stroke," *BMC Complementary and Alternative Medicine*, vol. 17, no. 1, p. 452, 2017.

- [3] Z. Hao, M. Liu, W. Li et al., "Basic characteristics and functional outcomes of 3123 consecutive patients in Chengdu stroke registry," *Chinese Journal of Neuromedicine*, vol. 44, no. 12, pp. 826–831, 2011.
- [4] Z. Wang, J. Li, C. Wang et al., "Correction: gender differences in 1-year clinical characteristics and outcomes after stroke: results from the China national stroke registry (PLoS ONE)," *Plos One*, vol. 8, no. 3, 2013.
- [5] B. Peng and B. Wu, "Chinese guideline for diagnosis and treatment of acute ischemic stroke 2018," *Chinese Journal of Neuromedicine*, vol. 55, no. 9, pp. 666–682, 2018.
- [6] B. Maïer, J. P. Desilles, and M. Mazighi, "Intracranial hemorrhage after reperfusion therapies in acute ischemic stroke patients," *Frontiers in Neurology*, vol. 11, Article ID 599908, 2020.
- [7] H.-G. Xie, Y.-M. Jia, T. Tai, and J.-Z. Ji, "Overcoming clopidogrel resistance: three promising novel antiplatelet drugs developed in China," *Journal of Cardiovascular Pharmacol*ogy, vol. 70, no. 6, pp. 356–361, 2017.
- [8] J. Lyu, Y. Xie, M. Sun, and L. Zhang, "Efficacy and safety of Xueshuantong injection on acute cerebral infarction: clinical evidence and GRADE Assessment," *Frontiers in Pharmacology*, vol. 11, p. 822, 2020.
- [9] M. Cheng, X. Bai, X. Lin et al., "Meta analysis of Xueshuantong combined with edaravone in the treatment of acute cerebral infarction," *Beijing Journal of Traditional Chinese Medicine*, vol. 37, no. 5, pp. 434–439, 2018.
- [10] F. Wu, G. Dai, X. Feng et al., "Meta-analysis of effectiveness and safety of butylphthalide capsules combined with Xueshuantong injection in the treatment of acute cerebral infarction," *China Pharmacist*, vol. 20, no. 2, pp. 314–317, 2017.
- [11] X. Wang, J. Wu, D. Zhang et al., "Meta-analysis of efficacy of Xueshuantong injection in the treatment of acute cerebral infarction," *Chinese Journal of Pharmacoepidemiology*, vol. 25, no. 10, pp. 616–622, 2016.
- [12] P. Yang, X. Song, and N. Chen, "Advances in pharmacological studies of Panax notoginseng saponins on brain ischemiareperfusion injury," *Acta Pharmaceutica Sinica*, vol. 51, no. 7, pp. 1039–1046, 2016.
- [13] W. Wang, M. Xue, L. Yang et al., "Experimental research on the protective effect of Panax notoginseng saponins on the gastric mucosa and the anti-platelet effect of aspirin based on arachidonic acid metabolic pathway," *Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease*, vol. 17, no. 9, pp. 1315–1320, 2019.
- [14] S. Guo, Q. Zhang, Z. Tian et al., "Effect of notoginseng total saponins combined with aspirin on platelet aggregation," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 24, no. 9, pp. 116–120, 2018.
- [15] Z. Sun, Y. Wang, W. Yang et al., "Research on the anti-platelet effects of Panax notoginseng saponins combined with aspirin based on molecular docking and in vivo experiments," *China Pharmacist*, vol. 23, no. 12, pp. 2317–2394, 2020.
- [16] Y. Hu and J. Wang, "Interactions between clopidogrel and traditional Chinese medicine," *Journal of Thrombosis and Thrombolysis*, vol. 48, no. 3, pp. 491–499, 2019.
- [17] J. Higgins and S. E. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0, The Cochrane Collaboration, London, UK, 2011.
- [18] H. Balshem, M. Helfand, H. J. Schünemann et al., "GRADE guidelines: 3. Rating the quality of evidence," *Journal of Clinical Epidemiology*, vol. 64, no. 4, pp. 401–406, 2011.

- [19] L. Zhang, "Effect of Xueshuantong Injection on Mrs score and Bi index in patients with acute ischemic stroke," *China Health Care Nutrition*, vol. 30, no. 19, p. 96, 2020.
- [20] S. Xiao, J. Liu, and B. Wang, "Efficacy of citicoline combined with Xuesaitong injection in patients with acute cerebral infarction and effect on the level of serum TLR4/NF - κ B signaling pathway," *The Journal of Molecular Diagnostics & Therapy*, vol. 12, no. 06, pp. 737–740+745, 2020.
- [21] J. Wang, Y. Cheng, Y. Liu et al., "Therapeutic effect of Xuesaitong injection combined with butylphthalide injection on cerebral infarction and its effect on NIHSS score and hemodynamics," *Chinese Archives of Traditional Chinese Medicine*, vol. 38, no. 8, pp. 122–124, 2020.
- [22] D. Huang, G. Feng, X. Mao et al., "Clinical effect of Ureklin combined with Xueshuantong on patients with the clinical effect of Urekrin combined with Xueshuantong on acute ischemic stroke andchanges of neurological deficit score and ability of daily living were analyzed," *Journal of International Psychiatry*, vol. 46, no. 6, pp. 1063–1066, 2019.
- [23] X. Zhang and Y. Luo, "Effect of Xueshuantong injection combined with cattle encephalon glycoside and ignotin in treatment of acute ischemic stroke and its influence on neurological function, cognitive function and activity of daily living," *Chinese Archives of Traditional Chinese Medicine*, vol. 37, no. 12, pp. 2983–2986, 2019.
- [24] Z. Xu, H. Li, and F. Yang, "Efficacy analysis of Xueshuantong injection combined with aspirin in the treatment of elderly patients with acute cerebral infarction," *Medical Innovation of China*, vol. 16, no. 5, pp. 136–140, 2019.
- [25] J. Xiao, J. Feng, T. Rong et al., "Effect of Xuesaitong Injection on ECG and hemorheology in patients with acute cerebral infarction," *Modern Journal of Integrated Traditional Chinese and Western Medicine*, vol. 28, no. 2, pp. 202–205, 2019.
- [26] Y. Wang, "Effect of Xueshuantong injection on inflammatory factor and prognosis in patients with acute cerebral infarction," *Medical Innovation of China*, vol. 16, no. 18, pp. 50–54, 2019.
- [27] Q. Sun, "Effect of Xuesaitong acupuncture on platelet parameters and hemorheology in 336 cases of ischemic cerebral infarction," *Journal of North Pharmacy*, vol. 16, no. 1, pp. 71-72, 2019.
- [28] J. Chen and H. Zhao, "Effect of Xueshuantong combined with atorvastatin and plavix on platelet aggregation, lipid metabolism and carotid atherosclerosis plaque in patients with acute cerebral infarction complicated with hyperlipidemia," *Chinese Journal of Thrombosis and Hemostasis*, vol. 24, no. 5, pp. 817–820, 2018.
- [29] W. Tan, Y. Zhang, H. Lu et al., "Effect of Xueshuantong on acute cerebral infarction and its influence on serum inflammatory factors," *Journal of Guangxi Medical University*, vol. 35, no. 11, pp. 1513–1516, 2018.
- [30] S. Ren, X. Li, N. Li et al., "Clinical study of conventional western medicine combined with Xueshuantong injection on acute ischemic stroke," *Hebei Journal of Traditional Chinese Medicine*, vol. 40, no. 6, pp. 885–889, 2018.
- [31] J. Ouyang, J. Huang, and J. Yang, "The curative effect of Xuesaitong injection combined with edaravone in treatment of acute cerebral infarction patients and serum high- sensitivity C reactive protein, homocysteine," *Neuron Specific Enolase, Chinese Journal of Thrombosis and Hemostasis*, vol. 23, no. 1, pp. 61–67, 2017.
- [32] S. Wang, P. Li, J. Liu et al., "Clinical observation of vinpocetine combined with Xueshuantong in the treatment of

cerebral infarction," China Pharmacy, vol. 28, no. 36, pp. 5079–5082, 2017.

- [33] Z. Feng, "Clinical effect of Xueshuantong combined with sodium ozagrel in the treatment of acute cerebral infarction and the effect on nerve function," *Journal of Qiqihar Medical College*, vol. 38, no. 13, pp. 1551-1552, 2017.
- [34] Y. Hu, X. Wang, and H. Shi, "Clinical curative effect of Xuesaitong Injection combined with edaravone in treatment of elderly patients with acute cerebral infarction and influence on Hemorheology of patients with plasma C reactive protein," *Journal of Qiqihar Medical College*, vol. 38, no. 2, pp. 170–172, 2017.
- [35] Y. Su, L. Kan, and X. Miao, "Clinical effects of Xueshuantong lyophilized powder on acute cerebral infarction and its effects on levels of plasma TNF-α, hcy, fib," *Journal of Hubei Uni*versity of Chinese Medicine, vol. 18, no. 6, pp. 31–33, 2016.
- [36] R. Zhang, G. Zhang, and J. Chen, "Effects of Xueshuantong injection on inflammatory cytokines, homocysteine and prognosis in patients with acute cerebral infarction," *Journal* of Hubei University of Chinese Medicine, vol. 18, no. 3, pp. 24–27, 2016.
- [37] Y. Huang, "Effect of Xuesaitong Injection on acute cerebral infarction and thrombosis," *Chinese Journal of Practical Nervous Diseases*, vol. 19, no. 5, pp. 102-103, 2016.
- [38] Y. Jiao, J. Li, and H. Li, "Effect of Xueshuantong Injection on serum high sensitivity C-reactive protein and interleukin-6 in patients with acute cerebral infarction," *Journal of Modern Integrated Chinese and Western Medicine*, vol. 25, no. 10, pp. 1097–1099, 2016.
- [39] Q. Zeng, "Intervention effect of Xueshuantong combined with edaravone on thrombosis of acute cerebral infarction," *Chinese Journal of Practical Nervous Diseases*, vol. 15, no. 23, pp. 115-116, 2015.
- [40] D. Sun, "Observation on the efficacy of combined therapy of thrombus and aspirin in the treatment of elderly patients with acute cerebral infarction," *China & Foreign Medical Treatment*, vol. 34, no. 33, pp. 139–141, 2015.
- [41] Y. Han, X. Zhong, and Y. Liu, "Effect of Xuesaitong on serum C-reactive protein level in the treatment of acute cerebral infarction and its clinical value," *Chinese Journal of Basic Medicine in Traditional Chinese Medicine*, vol. 20, no. 11, pp. 1529-1530, 2014.
- [42] D. Tang, "Alprostadil combined with Xueshuantong in the treatment of acute cerebral infarction," *China Practical Medical*, vol. 9, no. 30, pp. 116-117, 2014.
- [43] J. Wang and Y. Wang, "Clinical observation of ganglioside combined with Xuesaitong in the treatment of acute cerebral infarction," *Nei Mongol Journal of Traditional Chinese Medicine*, vol. 33, no. 17, pp. 18-19, 2014.
- [44] Y. Yu, S. Wu, and Q. Hou, "Clinical study on Xueshuantong combined with aspirinon in treatment of senium acute cerebral infarction," *Drugs & Clinic*, vol. 29, no. 7, pp. 782–785, 2014.
- [45] N. Li, Y. Han, D. Zheng et al., "Effect of Xueshuantong on serum D-dimer and high sensitivity C-reactive protein in patients with actue cerebral infarction," *Progress in Modern Biomedicine*, vol. 14, no. 7, pp. 1304–1307, 2014.
- [46] M. Cheng, H. Li, and S. Qi, "Influence of Xuesaitong injection to forming of acute cerebral infarction," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 20, no. 10, pp. 196–200, 2014.
- [47] X. Lu, "Effect of Xuesaitong injection on the expression of CD62P molecule in patients with acute cerebral infarction," *Clinical Medicine*, vol. 34, no. 08, pp. 13-14, 2014.

- [48] C. Yang, X. Meng, and Z. Wei, "Effect of Xuesaitong lyophilized powder on platelet activation markers in patients with acute cerebral infarction," *Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease*, vol. 21, no. 4, pp. 63–65, 2013.
- [49] L. Wang and Y. Lyu, "Treatment of acute cerebral infarction with integrated traditional Chinese and Western Medicine," *Journal of Changchun University of Traditional Chinese Medicine*, vol. 29, no. 05, pp. 870-871, 2013.
- [50] G. Zhao, M. Li, C. Li et al., "Clinical observation of panax Notoginoside injection on aute cerebral infarction," *China Prac Med*, vol. 7, no. 11, pp. 39-40, 2012.
- [51] K. Jiang and S. Jia, "Treatment of acute cerebral infarction with Xueshuantong," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 17, no. 22, pp. 242-243, 2011.
- [52] X. Luo, P. Wang, and X. Zeng, "Xue Sai Tong injection plus routine therapy for acute cerebral infarction and the influence on plasma C-reactive protein," *Clinical Journal of Practical Hospital*, vol. 8, no. 5, pp. 96–98, 2011.
- [53] X. Lei, G. Yang, and X. Cheng, "Effect of Sanqi Tongshu capsule combined with edaravone in the treatment of acute cerebral infarction and its influence on neurological function and cerebrovascular reserve capacity," *China Practical Journal* of *Medicine*, vol. 47, no. 6, pp. 114–117, 2020.
- [54] Y. Tian, J. Huo, X. Zhao et al., "Clinical study on Sanqi Tongshu Capsules combined with ganglioside in treatment of acute cerebral infarction," *Drugs & Clinic*, vol. 34, no. 11, pp. 3232–3235, 2019.
- [55] D. Wei, W. Shao, Z. Zhang et al., "Clinical observation of Sanqi Tongshu capsule combined with sodium ferulate in the treatment of acute ischemic cerebrovascular disease," *Nei Mongol Journal of Traditional Chinese Medicine*, vol. 36, no. 12, pp. 75-76, 2017.
- [56] J. Gou and S. Yu, "Clinical study on Sanqi Tongshu Capsules combined with sodium ferulate in treatment of acute ischemic cerebrovascular disease," *Drugs & Clinic*, vol. 31, no. 12, pp. 1896–1900, 2016.
- [57] H. Yang, G. Shao, X. Liu et al., "Observation on curative effect and hemorheology changes of Sanqi Tongshu capsule in the treatment of patients with acute cerebral infarction," *Journal* of Sichuan of Traditional Chinese Medicine, vol. 32, no. 1, pp. 152–154, 2014.
- [58] W. Li and Y. Wei, "Clinical effects of Xuesaitong soft capsule combined with atorvastatin in treating stroke patient and the effect on the PCSK9 thereof," *Journal of Nanhua University*, vol. 46, no. 4, pp. 405–427, 2018.
- [59] C. Li, C. Tang, and R. Fu, "Observation on the curative effect of Xuesaitong dropping pills in the adjuvant treatment of acute cerebral infarction," *Frontier of Medicine*, vol. 24, pp. 383-384, 2013.
- [60] Q. Wang, H. Li, X. Lv et al., "Effect of Xueshuantong capsule on clinical efficacy and neurological function in patients with progressive cerebral infarction," *Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease*, vol. 15, no. 24, pp. 3199–3201, 2017.
- [61] H. Sun, "Xueshuantong combined with aspirin in the treatment of acute cerebral infarction and its effect on S-100 β protein, *t*-PA and nerve function," *Journal of Mathematical Medicine*, vol. 34, no. 1, pp. 71–73, 2021.
- [62] Z.-y. Lin, L.-m. Chen, J. Zhang et al., "Ginsenoside Rb1 selectively inhibits the activity of L-type voltage-gated calcium channels in cultured rat hippocampal neurons," *Acta Pharmacologica Sinica*, vol. 33, no. 4, pp. 438–444, 2012.

- [63] Q. Shi, J. Xiang, X. Zhu et al., "Protective effects of Chinese herbal medicine naoshuantong on neurovascular unit in rats with cerebral ischemia/reperfusion injury," *Journal of Chinese Integrative Medicine*, vol. 10, no. 10, pp. 1135–1139, 2012.
- [64] S.-J. Hong, J.-B. Wan, Y. Zhang et al., "Angiogenic effect of saponin extract from Panax notoginseng on HUVECs in vitro and zebrafish in vivo," *Phytotherapy Research*, vol. 23, no. 5, pp. 677–686, 2009.
- [65] J. Wang, J. Xu, J. Zhong et al., "Effect of radix notoginseng saponins on platelet activating molecule expression and aggregation in patients with blood hyperviscosity syndrome," *Chinese Journal of Integrative Medicine*, vol. 24, no. 4, pp. 312–316, 2004.
- [66] I. G. Hovhannisyan and R. A. Hovhanessyan, "A comparative assessment of indicators of platelet aggregation and interleukins in patients with different outcomes of ischemic stroke," *Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova*, vol. 118, no. 9, pp. 22–25, 2018.
- [67] T. Uesugi, Y. Baba, S Kohara et al., "Clinical utility of platelet function testing following non-cardioembolic stroke," *The Tokai Journal of Experimental and Clinical Medicine*, vol. 40, no. 4, pp. 178–184, 2015.
- [68] J. P. Depta, J. Fowler, E. Novak et al., "Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack," *Stroke*, vol. 43, no. 9, pp. 2376–2381, 2012.
- [69] F. Sadeghi, S. Kovács, K. S. Zsóri, Z. Csiki, Z. Bereczky, and A. H. Shemirani, "Platelet count and mean volume in acute stroke: a systematic review and meta-analysis," *Platelets*, vol. 31, no. 6, pp. 731–739, 2020.
- [70] I. Ciancarelli, D. De Amicis, C. Di Massimo, C. Pistarini, and M. Giuliana Tozzi Ciancarelli, "Mean platelet volume during ischemic stroke is a potential pro-inflammatory biomarker in the acute phase and during neurorehabilitation not directly linked to clinical outcome," *Current Neurovascular Research*, vol. 13, no. 3, pp. 177–183, 2016.
- [71] W. Shen, J. Liu, X. Wu et al., "Current situation and promotion strategy of clinical trials of traditional Chinese medicine," *Acta Chinese Medicine and Pharmacology*, vol. 44, no. 5, pp. 1–4, 2016.
- [72] H. Li, X. Liao, R. Hu et al., "Analysis of status quo of RCT outcome indexes in treatment of acute ischemic stroke with traditional Chinese medicine," *China Journal of Chinese Materia Medica*, vol. 45, no. 9, pp. 2210–2220, 2020.
- [73] N. Li, W. Pang, H. Wang et al., "Analysis of outcome indicators of clinical trials of Chinese patent medicine in the treatment of acute cerebral infarction," *Tianjin Journal of Traditional Chinese Medicine*, vol. 37, no. 9, pp. 1034–1038, 2020.
- [74] L. Dai, C.-W. Cheng, R. Tian et al., "Standard protocol items for clinical trials with traditional Chinese medicine 2018: recommendations, explanation and elaboration (SPIRIT-TCM Extension 2018)," *Chinese Journal of Integrative Medicine*, vol. 25, no. 1, pp. 71–79, 2019.
- [75] C.-W. Cheng, T.-X. Wu, H.-C. Shang et al., "CONSORT extension for Chinese herbal medicine formulas 2017: recommendations, explanation, and elaboration (simplified Chinese version)," *Annals of Internal Medicine*, vol. 167, no. 2, pp. W21–W34, 2017.